CBD (Cannabidiol) studies around the world part 3
Cannabidiol Nausea Research
Cannabidiol has been shown to reduce vomiting and nausea-like behavior via a complex chemical mechanism that indirectly counteracts a certain group of autoreceptors in the human brain.
The first trials on cannabidiol’s effects on nausea were conducted on animals (mainly rats and shrews), and they found that CBD indeed seemed to suppress nausea and vomiting in those animals. However, since these animals were induced to nausea and vomiting via chemical means, it was still unclear how CBD would affect nausea induced by physical means or caused by illness.
However, more recent clinical studies conducted on human patients seem to confirm the above findings. Cannabidiol has been shown to regulate vomiting and reduce nausea-like symptoms in a wide range of illnesses. Additionally, CBD has also been shown to help alleviate chemotherapy-induced nausea and vomiting with surprising efficiency. This, combined with CBD’s pain relief and potential anti-carcinogenic properties, may one day lead to Cannabidiol being viewed as one of the most multi-faceted supplements to help patients undergoing chemotherapy.
Cannabidiol Pain Relief Research
Some doctors are now considering CBD to be an effective mild to moderately strong analgesic, prescribing Cannabidiol as a pain-reliever for patients with cancer-related pain, as well as other chronic pain such as central neuropathic pains.
While CBD’s pain-relief mechanisms are not yet fully understood, CBD is currently regarded as one of the safest cannabinoids and it has been shown to be effective against a number of cancer-related pains in numerous clinical trials.
CBD and other cannabinoids have also been shown to have effective analgesic properties for terminal cancer patients who have developed a resistance to strong opioid analgesics. This implies that Cannabidiol might be an effective alternative for pain relief even for patients whose bodies have become accustomed to high doses of powerful painkillers.
In certain cases, Cannabidiol is now regarded as a viable alternative to strong analgesics when it comes to chronic pain management. CBD is essentially a non-steroidal anti-inflammatory drug (a simple analgesic) and as such, CBD solutions are less powerful than opioid-based analgesics, but are generally considered to have far fewer side effects than these strong painkillers.
Additionally, Cannabidiol is also considered a means of pain relief for acute pain as well. While its direct analgesic properties seem less potent than most opioid painkillers, CBD’s synergistic effects against inflammation may mean that it will actually be more efficient against inflammatory pain than conventional analgesics.
Finally, CBD has been shown to ease pain caused by some chemotherapy drugs (primarily in breast cancer patients), which helps patients tolerate chemo treatments more easily and with less pain-related side effects.
A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.
An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain.
- John Yoda